(Q43655015)

25 November 2017

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women (English)

1 reference

25 November 2017

2

1 reference

25 November 2017

19

1 reference

25 November 2017

Christine Roberts

29

0 references

Joakim Dillner

21

object named as

Joakim Dillner

1 reference

25 November 2017

6

Cosette M Wheeler

1 reference

25 November 2017

18

Jorma Paavonen

1 reference

25 November 2017

25

Slawomir Majewski

1 reference

25 November 2017

1

Nubia Muñoz

1 reference

25 November 2017

9

Laura A Koutsky

1 reference

25 November 2017

Suzanne Marie Garland

13

object named as

Suzanne M Garland

1 reference

Francesc Xavier Bosch José

25 November 2017

20

object named as

F Xavier Bosch

1 reference

25 November 2017

Kristján Sigurdsson

3

1 reference

25 November 2017

Ole-Erik Iversen

4

1 reference

25 November 2017

Mauricio Hernandez-Avila

5

1 reference

25 November 2017

Gonzalo Perez

7

1 reference

25 November 2017

Darron R Brown

8

1 reference

25 November 2017

Eng Hseon Tay

10

1 reference

25 November 2017

Patricía J Garcia

11

1 reference

25 November 2017

Kevin A Ault

12

1 reference

25 November 2017

Sepp Leodolter

14

1 reference

25 November 2017

Sven-Eric Olsson

15

1 reference

25 November 2017

Grace W K Tang

16

1 reference

25 November 2017

Daron G Ferris

17

1 reference

25 November 2017

Warner K Huh

22

1 reference

25 November 2017

Elmar A Joura

23

1 reference

25 November 2017

Robert J Kurman

24

1 reference

25 November 2017

Evan R Myers

26

1 reference

25 November 2017

Luisa L Villa

27

1 reference

25 November 2017

Frank J Taddeo

28

1 reference

25 November 2017

Amha Tadesse

30

1 reference

25 November 2017

Janine T Bryan

31

1 reference

25 November 2017

Lisa C Lupinacci

32

1 reference

25 November 2017

Katherine E D Giacoletti

33

1 reference

25 November 2017

Heather L Sings

34

1 reference

25 November 2017

Margaret K James

35

1 reference

25 November 2017

Teresa M Hesley

36

1 reference

25 November 2017

Eliav Barr

37

1 reference

25 November 2017

Richard M Haupt

38

1 reference

25 November 2017

language of work or name

English

0 references

publication date

5 February 2010

1 reference

Journal of the National Cancer Institute

25 November 2017

1 reference

25 November 2017

102

1 reference

25 November 2017

5

1 reference

25 November 2017

325-339

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

25 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

HPV screening for cervical cancer in rural India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

The Bethesda System 2001: an update of new terminology for gynecologic cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP534

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJP534

1 reference

25 November 2017

1 reference